Plain-English translation of NCT05850234 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing , a new type of immunotherapy designed to help your immune system fight multiple myeloma. The medication works by taking your own T cells (a type of white blood cell) and enhancing them in the laboratory to recognize and attack cancer cells. Researchers want to see if this treatment is safe and effective for people whose myeloma has returned or stopped responding to previous treatments.
Multiple myeloma patients who have tried three or more standard treatments often have few options left, and their cancer frequently comes back. This medication targets two specific markers on myeloma cells, which may help the immune system attack the cancer more effectively than current approaches.
You likely qualify if…
You likely don't qualify if…
In this trial, you will receive the medication as an infusion (intravenous injection). The trial has two phases: the first phase tests the safest and best dose, while the second phase evaluates how well the treatment works. You will have regular clinic visits to monitor your response, check for side effects, and have blood tests and imaging done to track your myeloma.
AI-generated summary from trial data · Jun 26, 2026 · Not medical advice
United States